$NTHI

CHEN THOMAS C purchased $140K of NTHI

CHEN THOMAS C (CEO) purchased 36,259 shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at an average of $3.86 ($3.85–$4.04, $0.14M total) across 2 trades over 2026-08-14 to 2026-08-17.

Original reporting
SEC EDGAR · CHEN THOMAS C
Published Aug 18, 2026, 8:13 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 8:40 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTHI
Bullish
medium confidence
Mentioned
$NTHI
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTHIBullishLow
01

Why it matters

The CEO’s open-market purchase is a modest sentiment input but lacks accompanying guidance, financial results, or operational milestones in the filing text.

02

Market read

Traders may monitor for follow-on insider activity or subsequent company disclosures, but this filing alone is unlikely to drive a sustained repricing.

03

What to watch

The text does not state whether the purchase was funded by option exercises, prior sales, or personal tax planning, and it provides no 10b5-1 plan details.

Relevance 5/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-08-18)

Background

The article is an SEC Form 4 insider transaction disclosure for NEONC Technologies Holdings, Inc.

Company-level read

Ticker impact

$NTHIBullishMedium confidence
Context

SEC Form 4 shows CEO Chen Thomas C bought 36,259 shares of NEONC Technologies Holdings for about $140K at $3.85 to $4.04.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and should fade without follow-on company news.

Evidence & confidence

The filing is a primary-source insider transaction, but the disclosed size is relatively small and there is no 10b5-1 plan or accompanying operational update in the text.

Market effects

No sector-wide read-through is provided; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine liquidity or diversification rather than a strong valuation signal, especially without context on compensation or prior trading patterns.

Key entities

  • NEONC Technologies Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • CHEN THOMAS C

    CEO, officer/director/10% owner who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTHIMed

Stonegate, Inc.: Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

Stonegate Capital Partners updated coverage of NeOnc Technologies Holdings (NASDAQ: NTHI), citing 2Q26 progress for NEO100 and NEO212. NEO100 Phase 2a reported PFS at 6 months of 48.9% vs a 20% benchmark (p=0.0047), median OS 26.09 months, and no major toxicities. NeOnc plans a Type B FDA meeting; R&D rose to $2.6M from $0.7M year over year.

$NTHIMed

WallStreet-PR: NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Holdings (NASDAQ: NTHI) reported Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. It said six-month progression-free survival was 48.9% versus a 20% historical benchmark, with p=0.0047. Median overall survival was about 26 months, with no major toxicities. NeOnc plans an FDA meeting on next trial steps.

$NTHIMedAI 8/10

NeOnc Technologies Reports Positive Topline Data Of NEO100 Phase 2a Study, Stock Up In Pre-Market

NeOnc Technologies Holdings (NTHI) reported positive topline Phase 2a results for intranasal NEO100 (NEO100-01) in IDH1-mutant Grade IV glioma or Grade III astrocytoma. In 24 patients at 1,152 mg/day, six-month progression-free survival was 48.9% vs 20% expected. Median overall survival was 26.09 months. Company plans an FDA Type B meeting and will present full safety data.

$NTHIHighAI 9/10

Why is Neonc Technologies stock surging today?

Investing.com reports Neonc Technologies Holdings Inc (NTHI) shares rose 11.3% pre-open after its Phase 2a NEO100-01 intranasal NEO100 study in Grade III/IV IDH1-mutant glioma met the primary endpoint. Six-month progression-free survival was 48.9% vs a 20% benchmark (p=0.0047) in 24 patients. Company discussed efficacy, safety, and next regulatory steps.

$NTHIMedAI 8/10

NeOnc Technologies stock jumps on positive glioma trial data

NeOnc Technologies Holdings (NASDAQ:NTHI) shares rose 11.7% after positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. The study met its primary endpoint with 6-month progression-free survival of 48.9% vs a 20% benchmark (p=0.0047). Median overall survival was 26.09 months; 86.7% were alive at six months. The company plans an FDA Type B meeting.